Filters close
Released: 20-Apr-2021 8:05 AM EDT
Dana-Farber nurses present research at 2021 Oncology Nursing Society Congress
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting key studies at the 46th Annual Oncology Nursing Society (ONS) Congress. The presentations focus on the effects of the COVID-19 crisis, the need for diversity, equity and inclusion in oncology nursing as well as the critical role oncology nurse navigators play in a patient’s treatment plan.

26-Mar-2021 3:15 PM EDT
Expert panel issues recommendations for addressing cancer inequities
Dana-Farber Cancer Institute

Expert panel issues recommendations for addressing cancer inequities

19-Mar-2021 5:05 PM EDT
Study underscores need for multidisciplinary care for COVID-19 long-haulers
Dana-Farber Cancer Institute

A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.

11-Mar-2021 10:05 AM EST
Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer
Dana-Farber Cancer Institute

In two new studies published today in Cancer Cell, researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard used the emerging technology of single-cell RNA sequencing to draw a clearer picture of how kidney tumors’ microenvironments change in response to immunotherapy. The researchers believe that this work points to potential targets for new drug therapies.

24-Feb-2021 2:30 PM EST
CAR T-cell therapy generates lasting remissions in patients with multiple myeloma
Dana-Farber Cancer Institute

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

17-Feb-2021 3:05 PM EST
New recommendations aim to eliminate racial bias in myeloma trials
Dana-Farber Cancer Institute

Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites.

11-Feb-2021 4:05 PM EST
New immunotherapy target discovered for malignant brain tumors
Dana-Farber Cancer Institute

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.

13-Feb-2021 12:05 PM EST
Immunotherapy – targeted drug combination improves survival in advanced kidney cancer
Dana-Farber Cancer Institute

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

Released: 25-Jan-2021 12:05 PM EST
Dana-Farber to hold a discussion for cancer patients and survivors about the Covid-19 vaccine
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is having a virtual discussion for cancer patients and survivors about the Covid-19 vaccine on January 27, 2020 at 5 pm.

Released: 22-Jan-2021 1:45 PM EST
Dana-Farber research supports FDA approval for immunotherapy combination in advanced kidney cancer
Dana-Farber Cancer Institute

An immunotherapy agent combined with a tyrosine kinase inhibitor drug whose clinical testing as a first-line treatment in advanced kidney cancer was led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, has become a standard therapy.

Released: 22-Jan-2021 12:05 PM EST
Dana-Farber Cancer Institute opens new state-of-the-art location in Chestnut Hill
Dana-Farber Cancer Institute

With a major expansion of its world class oncology services, Dana-Farber Cancer Institute is opening a new hospital facility in Chestnut Hill to provide increased cancer care and outpatient services for adult patients in the region.

13-Jan-2021 12:05 PM EST
Study shows sharp decline in cancer screenings and diagnoses during the first COVID-19 surge
Dana-Farber Cancer Institute

In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and Women’s Cancer Center document a substantial decline in cancer and precancer diagnoses at the Northeast’s largest health care system during the first peak of the pandemic because of a drop in the number of cancer screening tests performed.

7-Jan-2021 12:05 PM EST
Study Finds New Evidence of Health Threat From Chemicals in Marijuana and Tobacco Smoke
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute and the Centers for Disease Control and Prevention have uncovered new evidence of the potential health risks of chemicals in tobacco and marijuana smoke.

6-Jan-2021 9:00 AM EST
Scientists create ON-OFF Switches to Control CAR T cell activity
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.

Released: 16-Dec-2020 10:05 AM EST
Eric P. Winer elected ASCO President for term starting in June 2022
Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) has elected  Eric P. Winer, MD, to serve as its President for the term beginning in June 2022.

Released: 14-Dec-2020 10:55 AM EST
John Ryan named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14. Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.

8-Dec-2020 2:40 PM EST
Adding immunotherapy to chemo improves responses without negatively impacting quality of life in patients with early-stage breast cancer
Dana-Farber Cancer Institute

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients’ ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women’s Cancer Center investigators shows.

3-Dec-2020 3:05 PM EST
Circulating tumor DNA indicates increased risk of relapse after stem cell transplant in patients with diffuse large B-cell lymphoma
Dana-Farber Cancer Institute

Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists suggests that patients whose blood or stem cell samples harbor tumor DNA are likely to relapse.

3-Dec-2020 2:30 PM EST
Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers
Dana-Farber Cancer Institute

The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.

3-Dec-2020 2:05 PM EST
CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
Dana-Farber Cancer Institute

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

3-Dec-2020 2:00 PM EST
Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants
Dana-Farber Cancer Institute

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don’t have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.

3-Dec-2020 1:35 PM EST
Donor stem cell transplant shown to improve survival in older patients with myelodysplastic syndrome
Dana-Farber Cancer Institute

A new clinical trial offers the most compelling evidence to date that a donor stem cell transplant can improve survival rates for older patients with higher-risk myelodysplastic syndrome (MDS), Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

2-Dec-2020 11:05 AM EST
Mortality rate after cancer surgery drops during 10-year period, but gap persists between Black and white patients
Dana-Farber Cancer Institute

Mortality rates after cancer surgery declined for Black as well as white patients during a recent ten-year period, although the mortality gap between the two groups did not narrow, according to new research by Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard University investigators.

Released: 1-Dec-2020 2:45 PM EST
Dana-Farber to present more than 40 research studies at 2020 ASH Annual Meeting
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology (ASH) Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

4-Nov-2020 2:05 PM EST
Medicaid expansion linked to lower mortality rates for three major types of cancer
Dana-Farber Cancer Institute

In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major forms of cancer are significantly lower than in states that have not expanded their Medicaid, a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard University shows.

24-Oct-2020 4:30 AM EDT
Targeted inhibitor of mutated KRAS gene shows promise in early trial for lung, bowel, and other solid tumors
Dana-Farber Cancer Institute

A novel agent that targets a mutated form of the KRAS gene – the most commonly altered oncogene in human cancers and one long considered “undruggable” – shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online.

Released: 6-Oct-2020 12:45 PM EDT
Study offers global review of impact of COVID-19 on cancer treatment and research
Dana-Farber Cancer Institute

The report, by researchers at Dana-Farber Cancer Institute and other institutions, suggests that while COVID-19 has complicated the treatment of cancer patients, it has also spurred creative solutions to challenges in clinical care, and research into the new disease is benefiting from insights gained over years of cancer research.

19-Sep-2020 12:05 AM EDT
Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer
Dana-Farber Cancer Institute

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

16-Sep-2020 1:05 PM EDT
Daily coffee consumption associated with improved survival in patients with metastatic colorectal cancer
Dana-Farber Cancer Institute

In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and a lower risk of the cancer worsening, researchers at Dana-Farber Cancer Institute and other organizations report in a new study.

Released: 24-Jul-2020 3:10 PM EDT
Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval
Dana-Farber Cancer Institute

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.

19-Jul-2020 7:05 AM EDT
Prostate cancer metastasis linked to revival of dormant molecular program
Dana-Farber Cancer Institute

When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute.

Released: 23-Jun-2020 10:00 AM EDT
Dana-Farber President & CEO Emeritus receives ASH Award for Leadership in Promoting Diversity
Dana-Farber Cancer Institute

Edward J. Benz, Jr., MD, President and CEO Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School, has received the 2020 ASH Award for Leadership in Promoting Diversity.

22-Jun-2020 9:00 AM EDT
Biomarker test highly accurate in detecting early kidney cancer
Dana-Farber Cancer Institute

A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute. The report in Nature Medicine suggests that if validated in larger trials and applied widely, the non-invasive test could find more early kidney cancers when they haven't spread, thus reducing the mortality of the disease.

22-Jun-2020 6:35 AM EDT
Online program significantly improves insomnia in adolescent and young adult cancer survivors, study finds
Dana-Farber Cancer Institute

In a study published today by Pediatric Blood and Cancer, researchers at Dana-Farber Cancer Institute show that an online program developed specifically for AYA cancer survivors can significantly alleviate insomnia and improve overall quality of life.

Released: 15-Jun-2020 9:20 AM EDT
Drug with new approach on impeding DNA repair shows promise in first clinical trial
Dana-Farber Cancer Institute

Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer

28-May-2020 11:05 AM EDT
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy
Dana-Farber Cancer Institute

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

Released: 26-May-2020 2:20 PM EDT
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants
Dana-Farber Cancer Institute

Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

19-May-2020 8:00 AM EDT
Dana-Farber to test blood cancer drug in COVID-19 patients
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus.

24-Apr-2020 3:05 PM EDT
Immune system changes occur early in development of multiple myeloma, study finds
Dana-Farber Cancer Institute

Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.

Released: 24-Apr-2020 4:25 PM EDT
Dana-Farber Cancer Institute faculty recognized as 2020 ASCO leaders in cancer research and care
Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) recognized four Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.

21-Apr-2020 2:30 PM EDT
New targeted agent produces considerable responses in trial with patients with uterine serous carcinoma
Dana-Farber Cancer Institute

The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial. Data will be shared virtually at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.

Released: 23-Apr-2020 2:05 PM EDT
SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank, a Population Health Initiative for Research and Education
Dana-Farber Cancer Institute

Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative -- a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.

Released: 15-Apr-2020 1:55 PM EDT
Massive study reveals how “hypermutated” malignant brain tumors with many mutations escape chemotherapy and immunotherapy
Dana-Farber Cancer Institute

An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.

Released: 7-Apr-2020 10:40 AM EDT
Dana-Farber scientists bring experience from SARS and MERS outbreaks to aid COVID-19 research
Dana-Farber Cancer Institute

As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders.The collection, created by Marasco and his associates in 1997 using blood samples from more than 57 Dana-Farber staff, has already had an illustrious history in the quest to tame viral disease outbreaks.

30-Mar-2020 8:25 AM EDT
New blood test can detect wide range of cancers, now available to at risk individuals in clinical study at Dana-Farber
Dana-Farber Cancer Institute

In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.

19-Feb-2020 3:45 PM EST
A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself
Dana-Farber Cancer Institute

Scientists find that normal intestinal cells “de-differentiate” en masse into stem cells that generate the cells needed for a healthy intestinal lining. New study establishes de-differentiation as the predominant mode of stem cell recover in the intestine

Released: 13-Feb-2020 12:45 PM EST
Novel targeted drug shows promise in advanced kidney cancer
Dana-Farber Cancer Institute

Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.

Released: 11-Feb-2020 10:00 AM EST
Dana-Farber Cancer Institute provides state-of-the-art oncology support services to Kronos employees through new company benefit
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute and Kronos Incorporated have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries.

19-Jan-2020 11:05 AM EST
Dozens of potential anti-cancer drugs netted in massive screening study
Dana-Farber Cancer Institute

A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.

Released: 13-Jan-2020 9:00 AM EST
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.



close
0.56837